Attached files
| file | filename |
|---|---|
| EX-23.2 - EXHIBIT 23.2 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex23-2.htm |
| EX-23.1 - EXHIBIT 23.1 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex23-1.htm |
| EX-10.9(A) - EXHIBIT 10.9(A) - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex10-9a.htm |
| EX-5.1 - EXHIBIT 5.1 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex5-1.htm |
| EX-4.2 - EXHIBIT 4.2 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex4-2.htm |
| EX-4.1 - EXHIBIT 4.1 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex4-1.htm |
| S-1 - S-1 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_s1.htm |
Exhibit 21.1
SUBSIDIARIES OF THE REGISTRANT
|
Subsidiary
|
State or Country of Organization
|
|
|
Brooklyn ImmunoTherapeutics LLC
|
Delaware
|
|
|
NTN Canada, Inc.
|
Canada
|
* Pursuant to Item 601(b)(21)(ii) of Regulation S-K, the names of other subsidiaries of the registrant are omitted because, considered in the aggregate, they would not constitute a significant subsidiary as of the end
of the year covered by this report.